RxSight makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. RXST reports earnings on Tue, Nov 3, 2026. Analyst consensus is Hold, based on the latest ratings from 4 firms (0 buy, 3 hold, 1 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 22 | Jefferies | Maintained | Hold | |
| Sep 22 | B of A Securities | Target lowered | Sell | |
| Aug 10 | Stifel | Maintained | Hold | |
| Aug 6 | UBS | Target raised | Hold | |
| Jul 28 | UBS | Assumed coverage | Hold |
Seasonality
How RXST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in RXST in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RXST is in one of them and how their past RXST trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered RXST in an article yet. Here's the latest on the wider market.
About RxSight
RxSight is a medical technology company based in Aliso Viejo, California. It makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. The system includes an implantable lens and a light device that uses ultraviolet light to change the lens's focusing power. Its customers are eye surgeons and ophthalmology practices, mainly in the United States, and its end users are patients undergoing cataract surgery.
- Headquarters
- Aliso Viejo, CA